EMN

Business Context and Reporting Period

Company: Eastman Chemical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: Eastman operates in five segments organized into two divisions: Eastman Division (Coatings, Adhesives, Specialty Polymers, and Inks; Performance Chemicals and Intermediates; Specialty Plastics) and Voridian Division (Polymers; Fibers). The company manufactures raw materials, additives, and specialty polymers for markets including paints, inks, adhesives, automotive, and consumer goods.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 8% year-over-year due to lower selling prices (primarily PET polymers), unfavorable product mix, and a stronger U.S. dollar. These factors were partially offset by a 5% volume increase driven by the Hercules acquisition.
• Profitability Drop: Operating earnings fell 20% to $77 million. The decline was driven by lower prices, foreign currency impacts, and reduced hedging gains, partially mitigated by lower raw material costs.
• Accounting Change Impact: Net earnings were significantly reduced by an $18 million after-tax charge recorded as the "cumulative effect of a change in accounting principle." This resulted from the adoption of SFAS No. 142, which required an impairment write-down of certain trademarks in the CASPI segment.
• Other Charges: "Other charges" increased to $16 million (from $6 million), including a $12 million foreign exchange loss on Argentine peso-denominated tax receivables and a $5 million nonrecurring charge related to the restructuring of Genencor International, Inc.
• Cash Flow Improvement: Operating cash flow swung from a $124 million use of cash in Q1 2001 to an $88 million generation in Q1 2002, reflecting improved working capital management.

Guidance, Outlook, and Risks

• Outlook: Management expects seasonal demand improvement in Q2 2002. Raw material costs are expected to rise, with the company planning to preserve margins through price increases and cost controls. Combined SG&A and R&D expenses are projected to be approximately 11% of sales.
• Capital Allocation: Capital spending is expected to remain at or below depreciation and amortization. Excess cash will be used to reduce debt, fund small acquisitions, and repurchase shares. The company expects to continue paying quarterly dividends ($0.44/share).
• Goodwill Impairment Test: The transitional impairment test for goodwill under SFAS No. 142 is expected to be completed by the end of Q2 2002. Any resulting charge will be recognized as a cumulative effect of a change in accounting principle.
• Risks:
  • Foreign Exchange: Continued devaluation of the Argentine peso could result in additional charges in Q2 2002.
  • Raw Materials: Volatility in paraxylene and ethylene glycol costs could impact Polymers segment margins.
  • Legal: Ongoing antitrust litigation regarding sorbates price-fixing (26 lawsuits pending, 23 settled). Management does not expect a material adverse effect on overall financial condition.

Investor Verification Checklist

• Accounting Change Impact: Verify the magnitude of the $18 million impairment charge related to SFAS No. 142 adoption and the timing of the pending goodwill impairment test results.
• Argentine Peso Exposure: Assess the remaining exposure to Argentine currency devaluation and the potential for further foreign exchange losses in Q2 2002.
• Segment Performance: Review the divergence between the CASPI segment (sales up 15%, earnings up 144%) and the PCI segment (sales up 17%, operating loss of $7 million) to understand product mix shifts.
• Debt Structure: Note the issuance of $400 million in 7% notes due 2012 in April 2002 (subsequent event) used to repay commercial paper and credit facility borrowings.
• Working Capital: Confirm the sustainability of the improved operating cash flow, which reversed a significant outflow from the prior year.